MRGPR X2 Modulators for IgE-Independent Mast Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for MRGPR X2 dependent conditions, such as pseudo-allergic reactions, chronic itch, inflammation disorders, pain disorders, and autoimmune diseases, are inadequate due to the limited understanding of these receptors and their role in mediating these conditions, particularly in mast cells and dorsal root ganglia.
Innovation Solution
Development of modulators, specifically inverse agonists and competitive antagonists, targeting MRGPR X2 to block activation by various ligands, including basic secretagogues, certain drugs, and neuropeptides, thereby reducing IgE-independent mast cell activation and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for MRGPR X2 dependent conditions, then existing therapeutic options are available, but treatment effectiveness is inadequate due to limited understanding of receptor function
Solution Approach 1:
The patent uses inverse agonists and competitive antagonists as intermediary substances to modulate MRGPR X2 receptor activity. These compounds serve as mediators that block the interaction between endogenous ligands (basic secretagogues, neuropeptides) and the receptor, thereby treating conditions without requiring complete understanding of all receptor pathways. The compounds include specific chemical structures with defined pharmacological properties that selectively target MRGPR X2.
2Adaptability or versatility
If MRGPR X2 is activated by ligands such as basic secretagogues and drugs, then physiological responses are triggered, but pathological conditions including pseudo-allergic reactions and chronic itch are mediated
Solution Approach 1:
The patent applies preliminary anti-action by administering inverse agonists and competitive antagonists before or during exposure to activating ligands. These modulators pre-block the MRGPR X2 receptor, preventing pathological activation by basic secretagogues, drugs, or neuropeptides. The compounds are designed to occupy the receptor binding site and inhibit ligand-induced conformational changes that lead to mast cell degranulation and inflammatory responses.
3Speed
If mast cells are activated through IgE-independent pathways via MRGPR X2, then rapid inflammatory responses occur, but this mechanism is not adequately targeted by current therapies
Solution Approach 1:
The patent applies local quality by developing modulators with specific affinity and selectivity for MRGPR X2 receptor subtype. The inverse agonists and competitive antagonists are designed to target the unique binding characteristics of MRGPR X2 while sparing other MRGPR subtypes and receptor families. This selective modulation allows targeted intervention in IgE-independent mast cell activation pathways without broadly suppressing all inflammatory responses.
Data Source
AI summary
Methods are provided for modulating MRGPR X2 generally, or for treating a MRGPR X2 dependent condition more specifically, by contacting the MRGPR X2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I):or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R1, R2, R3, R4, R5, R6 and Rx are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.